[
    [
        {
            "time": "",
            "original_text": "一季报出炉：药明、恒瑞等11企业盈利破10亿！白药净利下滑40%，成败皆因炒股？ 盈利能力下降",
            "features": {
                "keywords": [
                    "一季报",
                    "药明",
                    "恒瑞",
                    "云南白药",
                    "盈利",
                    "净利下滑",
                    "炒股"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "一季报出炉：药明、恒瑞等11企业盈利破10亿！白药净利下滑40%，成败皆因炒股？ 盈利能力下降",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 7,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 7,
                "Time_Proximity": 9,
                "Headline_Structure": 9,
                "Source_Recency": 9
            }
        },
        {
            "time": "",
            "original_text": "医药生物行业2020年及2021年一季度业绩综述：2020年营收增速有所下降 2021Q1业绩大幅回升",
            "features": {
                "keywords": [
                    "医药生物",
                    "2020年",
                    "2021年一季度",
                    "营收增速",
                    "业绩回升"
                ],
                "sentiment_score": 0.7,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "医药生物行业2020年及2021年一季度业绩综述：2020年营收增速有所下降 2021Q1业绩大幅回升",
                "Correlation": 7,
                "Sentiment": 6,
                "Importance": 8,
                "Impact": 6,
                "Duration": 8,
                "Entity_Density": 5,
                "Market_Scope": 9,
                "Time_Proximity": 8,
                "Headline_Structure": 7,
                "Source_Recency": 8
            }
        },
        {
            "time": "",
            "original_text": "云南白药拟斥资百亿元谋破局",
            "features": {
                "keywords": [
                    "云南白药",
                    "斥资",
                    "百亿",
                    "破局"
                ],
                "sentiment_score": 0.5,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医药"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "false",
                "ts_effect_direction": ""
            },
            "scores": {
                "News_content": "云南白药拟斥资百亿元谋破局",
                "Correlation": 10,
                "Sentiment": 7,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 9,
                "Headline_Structure": 8,
                "Source_Recency": 9
            }
        }
    ]
]